StockData

Amarin vs Vanda Pharmaceuticals

AMRN and VNDA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AMRN and VNDA compare

Amarin is the larger company, worth 22 times as much as Vanda Pharmaceuticals ($5.0B against $230M).

Vanda Pharmaceuticals grew revenue faster over the last twelve months (8.1% versus −22.3% for Amarin).

Amarin keeps more of each dollar of sales as profit, with a net margin of −10.9% compared with −120% at Vanda Pharmaceuticals.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAMRNVNDA
Size and price
Market cap$5.0B$230M
Share price$11.27$3.81
Change, 1 year−31.0%−12.4%
Change, 5 years−84.5%−77.0%
Beta (5Y)0.730.78
Employees80533
StockData Score
Total score1010
Valuation score03 (better)
Growth score12 (better)
Performance score3 (better)0
Health score6 (better)5
Dividend score00
Valuation
P/S28.3×1.0× (better)
P/B11.2×1.2× (better)
FCF yield–−60.8%
Fair value$7.02$8.53
Margin of safety−60.6%55.3% (better)
Growth
Revenue growth (TTM)−22.3%8.1% (better)
Revenue growth, 5Y average−19.0%−2.7% (better)
Profitability
Gross margin40.9%93.6% (better)
Operating margin−18.2% (better)−77.6%
Net margin−10.9% (better)−120%
FCF margin–−61.0%
Return on equity−4.2% (better)−82.5%
Return on invested capital−17.3% (better)−52.6%
Financial health
Debt / equity0.000.00
Current ratio3.50 (better)1.54
Altman Z-score12.89 (better)−1.85
Piotroski F-score7 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions1.0%82.2%
Held by insiders7.0%9.2%
Insider net buying, 12 months–−$2.8M
Short interest, % of float–13.9%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.